An observational study in Type 2 Diabetes, Insulin and Education, sponsored by King's College London. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by King's College London · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 573 studies in Diabetes Mellitus, Type 2 with a site in United Kingdom — 58 open to participants now, 74 under way, 20 of them phase 3. Diabetes Mellitus, Type 2 · United Kingdom.
Among the 573 studies in Diabetes Mellitus, Type 2 with a site in United Kingdom, this one is the 75th largest by planned enrollment of the 78 observational ones that give a count, is one of 22 that started in 2026, is one of 78 observational ones, reaches primary completion later than 36 of the 73 other live ones, and was the 571st registered.
10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →58 of the 573 studies in Diabetes Mellitus, Type 2 with a site in United Kingdom are open now. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18+
Ascletis Pharma (China) Co., Limited · Sites in United Kingdom, United States, Czechia and 3 more countries
Ages 18+
AstraZeneca · Sites in United Kingdom, United States, Argentina and 8 more countries
Ages 18+
Novo Nordisk A/S · Sites in United Kingdom, United States, Argentina and 13 more countries
Ages 45+
AstraZeneca · Sites in United Kingdom, United States, Argentina and 13 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
573 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 59 · Phase 3 187 · Phase 4 58
First in 1997; this study’s year is marked. 22 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 300 across 1,746 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 207 across the 495 interventional studies, 578 across the 78 observational. Of the 462 that completed or were terminated, 194 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
345 of 573 have an industry lead sponsor. The 10 most frequent:
King's College London is the lead sponsor of 524 studies on the registry; 130 are open to participants now.
King's College London has 6 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
17 of the studies in Diabetes Mellitus, Type 2 with a site in United Kingdom that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT06652763University of LeicesterManganese-enhanced Magnetic Resonance Imaging (MEMRI) in Heart Failure With Preserved Ejection Fraction | 2026-11 |
Add all 17 to your calendar (.ics) → With an account.
Among the 573 studies in Diabetes Mellitus, Type 2 with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to find out the views of nurses and inpatients with type 2 diabetes of the Diabetes Insulin self-Management Education (DIME) web-based application. DIME was developed by nurses and people with type 2 diabetes, and a prototype was developed. The DIME app has been developed over a long period of time in response to the needs and concerns of people with type 2 diabetes starting insulin and a pilot study which led to the development of the original DIME programme. The current study involves introducing the DIME app to a small number of people starting insulin in hospital and the nurses who educate them and interviewing them about their thoughts on using it. The investigators will also count the number of people with type 2 diabetes who start insulin in hospital and the main reason for starting it over a 6 month period.
This project will help us to understand if a digital tool such as DIME might help to support in hospital insulin starts. The investigators will also know how many people are likely to need the support as they will have counted the number of people starting insulin when they have type 2 diabetes in hospital over a 6 month period. It will involve patients and nurses. The nurses involved will understand how, what, when, and why new technology such as the DIME app can fit within the hospital setting.
The study has been designed to address the following questions:
What are the views of people living with type 2 diabetes and nurses on the use of a web-based app to support in-hospital insulin starts? How many people with type 2 diabetes start insulin in hospital over a 6 month period and what is the reason for starting it?
Introduction In 2021-22, there were 3.4 million adults living with type 2 diabetes (T2D) in England. Because this figure continues to rise while the age of T2D onset decreases concurrently, people have begun to live longer with diabetes and will likely need insulin to avoid micro-vascular complications. Insulin is a high-risk medication, presenting possible complications for people with T2D, and can be complex for healthcare professionals (HCP) to manage and support people with T2D. Current T2D NICE guidance suggests that insulin be used for individuals with an HbA1c ≥ 58 mmol/mol on 2 or more oral agents. Many people with T2D do not want to take insulin, an inclination exacerbated by the health system and how HCPs respond to people who need it. Even when people start insulin, 30-50% are not optimised in terms of achieving target glycaemia. In the community, a high proportion refuse to start insulin; consequently, they become unwell, are hospitalised, and initiate insulin in hospital. There are anecdotally 40-60 insulin starts per month at King's College Hospital but this figure needs to be confirmed, while there are 75% fewer in community clinics, where insulin initiation programmes have typically been run.
In many situations in which a patient does initiate insulin in hospital, they frequently receive instruction on injection techniques in a time-pressured situation. Nurses typically have around 30 minutes to complete the demonstration and patients may be left with an incomplete understanding about insulin or feel that their questions went unanswered. Additionally, nurses have expressed concern that they will forget to pass on important information that could cause harm to the patient. Digital resources such as web-based applications, however, offer a promising means by which patients can be supported with in hospital insulin initiation. Web-based resources can be easily accessed by mobile phone, tablet or PC and can provide a back-up if patients are discharged sooner than expected, with trusted information to refer back to.
In a previously written systematic review and meta-analysis of insulin education programmes, the investigators demonstrated that insulin education employing psychological techniques led to better glycaemic control. The findings were incorporated into a group-based Diabetes Insulin self-Management Education (DIME) programme, which was tested in community diabetes clinics. However, as fewer patients are seen in community clinics, attendance at education is low; because DIME required staff training, DIME was re-developed as a web-based application.
RATIONALE The aim of this project is to determine the views of nurses and inpatients with T2D of the DIME web-based application. DIME was co-designed and co-produced by nurses and people with T2D (manuscript in preparation), and a prototype was developed. The DIME web-based application is underpinned both by a previous qualitative study involving people with T2D who had recently started insulin, in addition to a pilot RCT which led to the development of the original DIME programme. The current project involves introducing the DIME web-based app resource with a small sample of people starting insulin in hospital and the nurses who educate them and interviewing them about their thoughts on using it. Concurrently, the number of people with T2D who start insulin in hospital will be counted and the main reason for starting it.
This project will help us to understand if a digital resource might help to support in hospital insulin initiation and determine the scale of the problem. It will therefore involve patients and nurses. The nurses involved will understand how, what, when, and why new technology such as the DIME digital assistant can fit within this complex clinical setting.
The study has been designed to address the following question:
What are the views of people living with T2D and nurses on the use of a web-based app to support in-hospital insulin initiation? How many people with T2D start insulin in hospital over a 6 month period and what is the reason for starting it?
Study Purpose and Objectives This is a non-commercial study.
Primary Objectives
Study Design To determine stakeholder views of the DIME web-based resource, this qualitative phase involves semi-structured interviews with people with T2D who started insulin in hospital, inpatient and diabetes nurses. There will also be an audit of the number of people with T2D starting insulin in hospital over a 6 month period and the reason for this.
Study Setting King's College Hospital is a large teaching hospital in south London with a large number of diabetes inpatients. Individual semi-structured interviews with 6-12 people with T2D who started insulin as an inpatient at King's College Hospital will be conducted. Consecutive convenience sampling will be used for this. Concurrently, individual semi-structured interviews with 4-6 inpatient and diabetes nurses will be conducted.
Participant selection Semi-structured interviews: adults aged 18 and above with T2D diagnosis who started insulin as an inpatient at King's College Hospital and willing to give their views on the DIME web-based app. Inpatient and diabetes nurses at King's College Hospital caring for people with T2D starting insulin in hospital and willing to give their views on DIME web-based app.
Observational study: number of people with T2D who start insulin in hospital will be counted and coded according to the reason they started insulin, i.e. acute hyperglycaemia, infection, MI, CVA etc
Participant inclusion criteria
Interview study:
Patient Participants:
Nurse Participants:
Participant exclusion criteria
Study procedures Participant recruitment Patient participants will be identified by their usual clinical care teams working at King's College Hospital. If eligible for the study, nurses who work in these settings will inform participants who meet the inclusion criteria of the study, and with their expressed interest and consent, introduce them to a researcher who will talk to them and give them the participant information sheet explaining the purpose of the study.
No one outside the direct care team will require access to the medical records of the participants.
Nurse participants will be invited to participate in the interviews by the Chief or Principal Investigator. If they are interested and provide consent, they will be informed of the study and given an opportunity to ask questions.
The number of people with T2D starting insulin in hospital will be collected by King's College Hospital diabetes nurses.
Screening Procedures Potential patient participants will be approached by diabetes healthcare professionals. The clinicians will invite potential participants and ask if they can give permission for the researchers to contact them. Alternatively, the clinicians will obtain consent from potential participants to pass on their contact details to the researchers should they express interest in participating.
Potential nurse participants will be approached to participate in the interviews with the Chief Investigator.
Schedule of Assessments for Each Visit Following consent being obtained the interviews will be conducted at the participants' choice of time/date. This could be on the same day as taking consent if this is convenient to the participant.
End of Study Definition For interview participants participation ends following the interview. The end of the study in its entirety will by at 6 months from study start to ensure the numbers of people starting insulin over a 6 month period are counted.
Data Collection Procedures The primary goal of the analysis will to be to identify participant views of the DIME web-based app. Recorded interviews will be transcribed verbatim and related files will be managed using NVivo software.
The second part of the analysis will be to count the number of people with T2D starting insulin in a 6 month period as inpatients in King's College Hospital. This data will be collated via the diabetes nurse team at King's College Hospital.
Data Recording/Reporting Results of the study will be reported in peer reviewed publications and used in subsequent grant applications. Participants who complete the interviews will have the opportunity to review their own transcripts.
Data Transfer to sites outside the Organisation No data will be transferred outside of KCL.
Data storage Data files/transcripts will be pseudoanonymised and stored on password protected KCL Cloud.
Regulatory Approvals The study protocol and other documentation will be submitted to the [state the name and address of the REC] before the start of the study.
Amendments Amendments will be submitted to the relevant regulatory bodies for review following sponsorship approval. Amendments will not be implemented without the required regulatory and site approvals in place, as determined by the HRA. Correspondence with the sponsor, REC and HRA will be retained.
End of Study Reporting End of Study Declaration The end of the study will be declared to the REC within 90 days of the study ending.
End of Study Reporting The end of the study report will be submitted to the REC within 12 months of the study ending.
Ethical considerations No major risk to the participants in the context of this study are anticipated. The study does not involve any invasive or ethically contentious activities. However, the focus of the study may raise issues for participants that could potentially raise emotional reactions. The research team has a high level of expertise in caring for this population and managing psychological distress, therefore we are confident that we will be to manage this sensitively and provide patients with any follow-up intervention they may need from the clinical team. If any concerns about participants are identified, appropriate action or referral shall be taken with the participating clinicians, and, where indicated, the local safe-guarding officer. Any adverse events arising in the conduct of the study will be recorded, reported to the principle and clinical investigator.
Potential benefits for adults with T2D includes the opportunity to speak about their experiences of using insulin to manage T2D. This may prove psychologically beneficial by offering peer support, feelings of empowerment with regards to informing new ways in which digital technology can support hospital insulin initiation. Additionally, participants may have the opportunity to use DIME in the future should it be made available.
Potential benefits of this project for nurses includes empowering nurses by looking to identify how digital technology can solve some of the current problems faced by diabetes nurses supporting people with T2D starting insulin in hospital. This project is nurse-led.
Safety \& Adverse Events Reporting An Adverse Event (AE) is any untoward medical occurrence in a participant that occurs as a result of the patient's involvement in the study.
A Serious Adverse Event (SAE) is an AE that results in one or more of the following:
No SAEs are expected as a result of this study. AEs that could occur might include distress about discussing diabetes treatment
Compliance and withdrawal Withdrawal/ drop out of participants Participants who have conducted the interview may withdraw from the study without giving a reason and their data will be destroyed up to the point at which the study report is written, within 3 months of their participation from the date on the consent form.
Protocol Compliance Deviations to the protocol will be documented and reported to the sponsor. Data Data to be collected
Qualitative data collection will involve 1 interview per participant following informed consent:
Other data:
Data handling and record keeping Semi-structured interview data will be recorded using an encrypted audio-recorder or via MS Teams. Data will be transcribed using a university approved transcriber or by the research team.
Interview transcripts will be pseudo anonymised.
Records retention and archiving, data to be kept for 5 years and stored on KCL Cloud via password protection.
No personal information will be kept once study reports prepared/published.
UK General Data Protection Regulation and Data Protection Act 2018 will be adhered to.
Access to the dataset Only the principal investigator, chief investigator and research assistant will have access to the data. University approved transcription service may be used and have access to pseudonymised transcript data.
Data considerations No statistician as this is a qualitative study Sample size calculation As this is a qualitative study, the concept of information power will be used to determine the sample size. This is dependent on the depth of information gleaned from the interviews, the more depth the fewer interviews required as well as whether the aims and objectives of the study are met (12). Therefore, the aim is to interview 4-6 nurses and 6-12 people with T2D.
Data analysis
The primary goal of the analysis will to be to identify participant views of the DIME web-based app. Recorded interviews will be transcribed verbatim and related files will be managed using NVivo software. Transcripts will be analysed using framework analysis. Framework analysis involves 5 stages: 1) familiarisation and close reading of interview transcripts and audio-files; 2) generation of initial codes and a thematic framework by two researchers independently; 3) indexing and applying the framework to the dataset; 4) charting of the data; 5) mapping and interpretation of the framework to the coded data.
The second part of the analysis will be to count the number of people with T2D starting insulin in a 6 month period as inpatients in King's College Hospital. This data will be collated via the diabetes nurse team at King's College Hospital.
Risk Management \& Safeguarding For the participants taking part in the interviews and workshops, the opportunity to share their own experiences, listen to others and relate to common experiences may be psychologically beneficial and offer people various perspectives of diagnosis and adaptation to life with diabetes. However, for some, the narrative of their own experience or that of others may induce feelings of discomfort, distress or anxiety which might not have been expressed previously. The researcher will aim at minimizing this risk by being mindful of potential reactions during the data collection process. This will be done by developing an interview guide on the basis of a literature review and asking the patients in the advisory group for comments. Also any signs of distress or anxiety exhibited by the participants will be addressed and they will be offered the chance to terminate the interview. They will be referred to appropriate follow-up and given contact details for additional support.
The lead researcher is an experienced clinician and has experience in conducting interviews. These skills will also be utilized where appropriate during the interaction with the participants.
All the researchers involved in the study will have safe-guarding training and will adhere to the safeguarding policies of KCL and the participating NHS Trust. Any adverse occurrences that occur during the study will be logged and reported to the PI and CI for appropriate action. They will also be presented anonymously to the advisory board.
It is not thought that there are any risks to researchers in excess of those already posed to them as clinicians working in a hospital setting.
Another risk is that of data protection and security. All personal data will be kept confidential in line with NHS Code of Confidentiality. Contact details (email, telephone numbers, and/or addresses) of participants will be kept in a file, in a locked filing cabinet in a locked office at a King's College London University campus. Audiotapes of any interviews will be also kept in a locked filing cabinet. Typed transcripts of the interviews/workshops will be stored on a University password-protected computer in a locked office at the University. Password-protected laptops may be used to transcribe interviews, these will be kept in the locked office when not in use. Only the research team, will have access to password protected computers/laptops which contain data for this research, in addition to locked filing cabinets. Once a participant has provided informed consent they will be assigned an ID number for the study which will be recorded on all study documents and will link the study documents to the participants name. The participant's name will not be recorded on any study document other than the informed consent form and Participant ID log.
The main burden will be the time commitment to completing the consent procedures and interview. Participants will be free to withdraw from the study at any point.
Insurance The study is sponsored by King's College London (KCL). The sponsor will, at all times, maintain adequate insurance in relation to the study through its professional indemnity (Clinical Trials) \& no fault compensation in respect of any claims arising as a result of negligence by its employees, brought by or on behalf of a study participant (with certain restrictions).
Publication and Dissemination Publication The research will be prepared for publication in peer reviewed journals and conference abstract submitted. All proposed publications will be discussed with the Sponsor.
Informing participants Study results will be automatically provided to participants.
Disclosure of Interests No competing interests to report.
People with type 2 diabetes starting insulin in hospital and the nurses who support them
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient Participants:
Nurse Participants:
Exclusion Criteria:
people with type 2 diabetes starting insulin in hospital and the nurses who support them
views of DIME
We will interview people about the DIME web-based app to see what they think about it
Time frame: participants interviewed on one occasion only, on day 1
Plan to share: No — This is qualitative interview data
Start is estimated for Dec 2026; primary completion for Jun 2027, 5 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.